Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
11Customers
2Debt Items
10Related Chains
Source-Backed Evidence Depth
Krystal Biotech, Inc. (KRYS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
1Distinct source URLs
3High confidence
0.683Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from MREO graph: o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In t…
Krystal Biotech, Inc. Customers
Ticker
Name
Confidence
Evidence
F-10-KRYSTAL-BIOTECH-INC
F-10-KRYSTAL-BIOTECH-INC
62%
to like-kind financial instruments and models that use readily observable market data as their basis. F-10 Krystal Biotech, Inc. Notes to Consolidated Financial Statements—Continued Revenue Recogniti…
F-11-KRYSTAL-BIOTECH-INC
F-11-KRYSTAL-BIOTECH-INC
62%
uct returns to date, and accordingly no allowance for returns was recorded for the year ended December 31, 2025. F-11 Krystal Biotech, Inc. Notes to Consolidated Financial Statements—Continued Cost o…
F-12-KRYSTAL-BIOTECH-INC
F-12-KRYSTAL-BIOTECH-INC
62%
s and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are …
F-13-KRYSTAL-BIOTECH-INC
F-13-KRYSTAL-BIOTECH-INC
62%
s and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are …
F-14-KRYSTAL-BIOTECH-INC
F-14-KRYSTAL-BIOTECH-INC
62%
. The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliatio…
F-3-KRYSTAL-BIOTECH-INC
F-3-KRYSTAL-BIOTECH-INC
62%
ate accrual because of the audit effort involved in determining the nature and extent of procedures to be performed. The following are the primary procedures we performed to address the critical audi…
F-4-KRYSTAL-BIOTECH-INC
F-4-KRYSTAL-BIOTECH-INC
62%
ate accrual because of the audit effort involved in determining the nature and extent of procedures to be performed. The following are the primary procedures we performed to address the critical audi…
F-5-KRYSTAL-BIOTECH-INC
F-5-KRYSTAL-BIOTECH-INC
62%
ate accrual because of the audit effort involved in determining the nature and extent of procedures to be performed. The following are the primary procedures we performed to address the critical audi…
F-6-KRYSTAL-BIOTECH-INC
F-6-KRYSTAL-BIOTECH-INC
62%
ate accrual because of the audit effort involved in determining the nature and extent of procedures to be performed. The following are the primary procedures we performed to address the critical audi…
F-8-KRYSTAL-BIOTECH-INC
F-8-KRYSTAL-BIOTECH-INC
62%
ate accrual because of the audit effort involved in determining the nature and extent of procedures to be performed. The following are the primary procedures we performed to address the critical audi…
ORGANIZATION-KRYSTAL-BIOTECH-INC
ORGANIZATION-KRYSTAL-BIOTECH-INC
62%
ate accrual because of the audit effort involved in determining the nature and extent of procedures to be performed. The following are the primary procedures we performed to address the critical audi…
Krystal Biotech, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
KRYS-DEBT
Debt stack $4.3M
90%
Market cache reports total debt of $4.3M.
KRYS-DEBT-10572
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
Krystal Biotech, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Krystal Biotech, Inc..
Krystal Biotech, Inc. Ownership
Holder
Name
Confidence
Evidence
KRYS-OWNER-AVORO-CAPITAL-ADVISORS-LLC
Avoro Capital Advisors LLC
90%
13F overlay lists Avoro Capital Advisors LLC as top holder; 370 tracked holders.
Krystal Biotech, Inc. Extended Supply Chain Network
